Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

@article{Lainka2002MarkedDI,
  title={Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.},
  author={Elke Lainka and Selda Oezbek and Manfred Falck and Jennifer M Ndagijimana and Tim Niehues},
  journal={Pediatrics},
  year={2002},
  volume={110 5},
  pages={e56}
}
OBJECTIVE To assess the effects of antiretroviral combination therapy that contains protease inhibitor (PI) on carbohydrate and lipid metabolism in human immunodeficiency virus (HIV)-infected children. METHODS A cross-sectional, descriptive clinical study was conducted in an outpatient clinic. Thirty-seven HIV-infected children who ranged from 1 to 17 years of age received nucleoside reverse transcriptase inhibitor treatment together with PI (PI group, n = 25) or without PI (non-PI group, n… CONTINUE READING